Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01649557
Other study ID # 331-08-210
Secondary ID
Status Completed
Phase Phase 2
First received July 20, 2012
Last updated September 29, 2015
Start date August 2009
Est. completion date September 2011

Study information

Verified date September 2015
Source Otsuka Pharmaceutical Development & Commercialization, Inc.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This will be a multicenter, 52 week, open label study to assess the safety and tolerability of oral OPC-34712 (1 to 6 mg) as monotherapy in adult patients with schizophrenia. The study will be conducted on an outpatient basis. Enrollment into the study will be drawn from eligible subjects who have completed participation in Study 331-07- 203 and who, in the investigator's judgment, would benefit from continued treatment with oral OPC-34712.


Recruitment information / eligibility

Status Completed
Enrollment 244
Est. completion date September 2011
Est. primary completion date August 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 67 Years
Eligibility Inclusion Criteria:

1. Subjects who participated in 331-07-203 and who, in the opinion of the investigator, have the potential to benefit from continued administration of OPC-34712 for the treatment of schizophrenia.

2. Outpatient status at last visit of Study 331-07-203.

Exclusion Criteria:

1. Sexually active males who are not practicing two different methods of birth control during the study and for 90 days after the last dose of study medication or who will not remain abstinent during the study and for 90 days after the last dose, or sexually active females of childbearing potential who are not practicing two different methods of birth control during the study and for 30 days after the last dose of study medication or who will not remain abstinent during the study and for 30 days after the last dose. If employing birth control, two of the following precautions must be used: vasectomy, tubal ligation, vaginal diaphragm, intrauterine device, birth control pill, birth control depot injection, birth control implant, condom, or sponge with spermicide.

2. Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving open-label OPC-34712.

3. Subjects who during the course of their participation in 331-07-203 were treated in violation of the protocol or who developed ANY exclusion criteria during the course of their participation.

4. Subjects who do not continue to meet all applicable inclusion/exclusion criteria for Protocol 331-07-203 at the last visit (ie, Week 6) of Protocol 331-07-203.

5. Subjects who represent a risk of committing suicide based on an answer of "Yes" to either Question 4 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan) or Question 5 (Active Suicidal Ideation with Specific Plan and Intent) on the "Suicidal Ideation" portion of the C-SSRS, or an answer of "Yes" to any of the suicide-related behaviors (actual attempt, interrupted attempt, aborted attempt, preparatory acts or behavior) on the "Suicidal Behavior" portion of the C-SSRS. A subject who has had any suicidal ideation within the last 6 months, any suicidal behaviors within the last two years, or who in the clinical judgment of the investigator presents a serious risk of suicide should be excluded from the study.

6. Subjects who would be likely to require prohibited concomitant therapy during the study.

7. Any subject who, in the opinion of the investigator, should not participate in the study.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
OPC-34712
oral administered once daily

Locations

Country Name City State
Bulgaria Otsuka Investigational Site Burgas
Bulgaria Otsuka Investigational Site Kazanlak
Bulgaria Otsuka Investigational Site Pazardzhik
Bulgaria Otsuka Investigational Site Plovdiv
Bulgaria Otsuka Investigational Site Radnevo
Bulgaria Otsuka Investigational Site Ruse
Croatia Otsuka Investigational Site Rijeka
Croatia Otsuka Investigational Site Zagreb
India Otsuka Investigational Site Ahmedabad Gujarat
India Otsuka Investigational Site Bangalore Karna
India Otsuka Investigational Site Chennai Tamilnadu
India Otsuka Investigational Site Mangalore Karna
India Otsuka Investigational Site Mangalore Karna
India Otsuka Investigational Site Pune Mahara
India Otsuka Investigational Site Varanasi Uttar Prad
India Otsuka Investigational Site Vijaywada Andh Prad
India Otsuka Investigational Site Visakhapatnam Andh Prad
Korea, Republic of Otsuka Investigational Site Chuncheon
Korea, Republic of Otsuka Investigational Site Incheon
Korea, Republic of Otsuka Investigational Site Incheon
Korea, Republic of Otsuka Investigational Site Seoul
Philippines Otsuka Investigational Site Cebu City
Philippines Otsuka Investigational Site Mandaluyong City
Romania Otsuka Investigational Site Arad
Romania Otsuka Investigational Site Bucuresti
Romania Otsuka Investigational Site Bucuresti
Romania Otsuka Investigational Site Bucuresti 2
Romania Otsuka Investigational Site Bucuresti 3
Romania Otsuka Investigational Site Cluj - Napoca
Romania Otsuka Investigational Site Oradea
Russian Federation Otsuka Investigational Site Moscow
Russian Federation Otsuka Investigational Site Moscow Region
Russian Federation Otsuka Investigational Site St. Petersburg
Russian Federation Otsuka Investigational Site St. Petersburg
Russian Federation Otsuka Investigational Site St. Petersburg
Russian Federation Otsuka Investigational Site Zagorodnoye
Serbia Otsuka Investigational Site Belgrade
Serbia Otsuka Investigational Site Belgrade 2
Serbia Otsuka Investigational Site Kragujevac
Serbia Otsuka Investigational Site NoviSad
Slovakia Otsuka Investigational Site Bojnice
Slovakia Otsuka Investigational Site Bratislava
Slovakia Otsuka Investigational Site Liptovsky Mikulas
Slovakia Otsuka Investigational Site Rimavska Sobota
Slovakia Otsuka Investigational Site Zilina
Taiwan Otsuka Investigational Site Hualian
Taiwan Otsuka Investigational Site Taipei
Ukraine Otsuka Investigational Site Chernigiv
Ukraine Otsuka Investigational Site Dnipropetrovsk
Ukraine Otsuka Investigational Site Kyiv
Ukraine Otsuka Investigational Site Kyiv
Ukraine Otsuka Investigational Site Kyiv
Ukraine Otsuka Investigational Site Simferopol
Ukraine Otsuka Investigational Site Stepanivka
Ukraine Otsuka Investigational Site Vinnytsya
United States Otsuka Investigational Site Austin Texas
United States Otsuka Investigational Site Bradenton Florida
United States Otsuka Investigational Site Cedarhurst New York
United States Otsuka Investigational Site Escondido California
United States Otsuka Investigational Site Garden Grove California
United States Otsuka Investigational Site Little Rock Arkansas
United States Otsuka Investigational Site Long Beach California
United States Otsuka Investigational Site Maitland Florida
United States Otsuka Investigational Site Oceanside California
United States Otsuka Investigational Site Pasadena California
United States Otsuka Investigational Site Philadelphia Pennsylvania
United States Otsuka Investigational Site San Diego California
United States Otsuka Investigational Site San Diego California
United States Otsuka Investigational Site Santa Ana California
United States Otsuka Investigational Site St. Louis Missouri
United States Otsuka Investigational Site Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
Otsuka Pharmaceutical Development & Commercialization, Inc.

Countries where clinical trial is conducted

United States,  Bulgaria,  Croatia,  India,  Korea, Republic of,  Philippines,  Romania,  Russian Federation,  Serbia,  Slovakia,  Taiwan,  Ukraine, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Adverse Events (AEs) During First 6 Weeks. AE was defined as any new medical problem, or exacerbation of an existing problem, experienced by a participant while enrolled in the trial, whether or not it was considered drug related by the investigator. A serious adverse event (SAE) was any untoward medical occurrence that resulted in death or was life-threatening or required inpatient hospitalization or prolonged hospitalization. A treatment-emergent AE (TEAE) was defined as an AE that started after start of study medication or an AE that continued from baseline and that worsened, was serious, was study medication related, or resulted in death, discontinuation, interruption, or reduction of study medication. From Baseline up to 6 weeks Yes
Primary Number of Participants With AEs in 52-Week Enrollers. AE was defined as any new medical problem, or exacerbation of an existing problem, experienced by a participant while enrolled in the trial, whether or not it was considered drug related by the investigator. A SAE was any untoward medical occurrence that resulted in death or was life-threatening or required inpatient hospitalization or prolonged hospitalization. A TEAE was defined as an AE that started after start of study medication or an AE that continued from baseline and that worsened, was serious, was study medication related, or resulted in death, discontinuation, interruption, or reduction of study medication. From Baseline up to 52 weeks Yes
Secondary Change From Baseline in Total Score of Positive and Negative Syndrome Scale (PANSS) by Study Week and at the Last Visit. The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 that indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. The PANSS total score was the sum of the rating scores for 7 positive subscale items, 7 negative subscale items, and 16 general psychopathology subscale items from the PANSS panel. The PANSS total score ranges from 30-210, with higher scores indicating more severe symptoms. Baseline, Day 4, Week 1, 2, 4, 6, 8, 14, 20, 26, 32, 38, 44, 52 and Last Visit No
Secondary Change From Baseline in Clinical Global Impression- Severity of Illness Scale (CGI-S) Score. The severity of illness for each participant were rated using the CGI-S. To perform this assessment, the investigator were to answer the following question: "Considering your total clinical experience with this particular population, how mentally ill was the participant at that time?" Response choices include: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants. Baseline, Day 4, Week 1, 2, 4, 6, 8, 14, 20, 26, 32, 38, 44, 52 and Last Visit No
Secondary Change From Baseline in Personal and Social Performance Scale (PSP) Total Score. The PSP was a validated clinician-rated scale that measured personal and social functioning in four domains: socially useful activities (e.g, work and study), personal and social relationships, self-care, and disturbing and aggressive behaviors. Impairment in each of these domains was rated as absent, mild, manifest, marked, severe, or very severe. These ratings were then converted to a total score based on a 100-point scale using algorithms to identify the appropriate 10-point interval, and the rater's judgment that determined the total score within the 10-point interval. Participants with a PSP total score of 71 to 100 were considered to have mild functional difficulty. Scores of 31 to 70 represented manifest disabilities of various degrees and ratings of 1 to 30 indicated minimal functioning that required intense support and/or supervision. Baseline, Week 1, 2, 6, 26, 52 and Last Visit No
Secondary Mean Clinical Global Impression- Improvement Scale (CGI-I) Total Score. The efficacy of study medication was rated for each participant using the CGI-I. The investigator rated the participants total improvement whether or not it was due to the drug treatment. All responses were compared to the participants condition at Screening/Baseline (i.e, Week 6 visit of Protocol NCT00905307). Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. Day 4, Week 1, 2, 4, 6, 8, 14, 20, 26, 32, 38, 44, 52 and Last Visit No
Secondary Change From Baseline in PANSS Positive Subscale Score. The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In positive subscale, the 7 positive symptom constructs were: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS positive symptom score ranges from 7-49, with higher scores indicating more severe symptoms. Baseline, Day 4, Week 1, 2, 4, 6, 8, 14, 20, 26, 32, 38, 44, 52 and Last Visit No
Secondary Change From Baseline in PANSS Negative Subscale Score. The PANSS consisted of three subscales that contained a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 indicated the absence of symptoms and a score of 7 indicated extremely severe symptoms. In negative subscale the severity was rated for the following 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS negative symptom score ranges from 7-49, with higher scores indicating more severe symptoms. Baseline, Day 4, Week 1, 2, 4, 6, 8, 14, 20, 26, 32, 38, 44, 52 and Last Visit No
Secondary Percentage of Participants With a Positive Response Rate. Response rate was defined as a reduction of = 30% from Baseline in PANSS total score or CGI-I score of 1 (very much improved) or 2 (much improved) at the Last Visit. Last Visit No
Secondary Percentage of Participants Who Discontinued Due to Lack of Efficacy. Discontinuation rate for the participants discontinued due to lack of efficacy were examined. Last Visit No
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A